Edwards Lifesciences Corp
For the period ended Dec 31, 2023. Filed Feb 12, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 12, 2024
EW$104.01-0.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders' Equity
| Common Stock · Treasury Stock | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Par Value · Shares · Amount · Additional Paid-in Capital · Retained Earnings · Accumulated Other Comprehensive Loss · Total Edwards Lifesciences Corporation Stockholders' Equity · Noncontrolling Interest · Total Stockholders'Equity | |||||||||||||||||||
| BALANCE AT DECEMBER 31, 2020 | 636.4 | $636.4 | 12.1 | $(1,904.1) | $1,438.1 | $4,565.0 | $(161.1) | $4,574.3 | $— | $4,574.3 | |||||||||
| Net income | 1,503.1 | 1,503.1 | 1,503.1 | ||||||||||||||||
| Other comprehensive loss, net of tax | 3.4 | 3.4 | 3.4 | ||||||||||||||||
| Common stock issued under equity plans | 5.6 | 5.6 | 153.0 | 158.6 | 158.6 | ||||||||||||||
| Stock-based compensation expense | 109.3 | 109.3 | 109.3 | ||||||||||||||||
| Purchases of treasury stock | 5.8 | (512.8) | (512.8) | (512.8) | |||||||||||||||
| BALANCE AT DECEMBER 31, 2021 | 642.0 | 642.0 | 17.9 | (2,416.9) | 1,700.4 | 6,068.1 | (157.7) | 5,835.9 | — | 5,835.9 | |||||||||
| Net income | 1,521.9 | 1,521.9 | — | 1,521.9 | |||||||||||||||
| Other comprehensive income, net of tax | (97.2) | (97.2) | (97.2) | ||||||||||||||||
| Common stock issued under equity plans | 4.3 | 4.3 | 142.1 | 146.4 | 146.4 | ||||||||||||||
| Stock-based compensation expense | 126.8 | 126.8 | 126.8 | ||||||||||||||||
| Purchases of treasury stock | 20.1 | (1,727.1) | (1,727.1) | (1,727.1) | |||||||||||||||
| BALANCE AT DECEMBER 31, 2022 | 646.3 | 646.3 | 38.0 | (4,144.0) | 1,969.3 | 7,590.0 | (254.9) | 5,806.7 | — | 5,806.7 | |||||||||
| Net income (loss) | 1,402.4 | 1,402.4 | (3.0) | 1,399.4 | |||||||||||||||
| Other comprehensive loss, net of tax | 12.1 | 12.1 | 12.1 | ||||||||||||||||
| Common stock issued under equity plans | 4.2 | 4.2 | 165.7 | 169.9 | 169.9 | ||||||||||||||
| Stock-based compensation expense | 139.4 | 139.4 | 139.4 | ||||||||||||||||
| Purchases of treasury stock | 11.4 | (880.5) | (880.5) | (880.5) | |||||||||||||||
| Changes to noncontrolling interest (Note 9) | — | 72.4 | 72.4 | ||||||||||||||||
| BALANCE AT DECEMBER 31, 2023 | 650.5 | $650.5 | 49.4 | $(5,024.5) | $2,274.4 | $8,992.4 | $(242.8) | $6,650.0 | $69.4 | $6,719.4 | |||||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.